Pathstone Family Office’s Iovance Biotherapeutics IOVA Stock Holding History

Pathstone Family Office’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$47.9K	Buy	+10,519	New	+$68.7K	﹤0.01%	1627
2019 Q1	–	Sell	-335	Closed	-$3K	–	921
2018 Q4	$3K	Hold	335	–	–	﹤0.01%	423
2018 Q3	$4K	Buy	335 +200	+148%	+$2.84K	﹤0.01%	191
2018 Q2	$2K	Sell	135 -200	-60%	-$2.92K	﹤0.01%	146
2018 Q1	$5K	Hold	335	–	–	﹤0.01%	285
2017 Q4	$3K	Hold	335	–	–	﹤0.01%	122
2017 Q3	$3K	Buy	+335	New	+$2.12K	﹤0.01%	159

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Family Office's IOVA Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Iovance Biotherapeutics (IOVA) in Q3 2023: 10,519 shares worth $47.9K. The stake represents ﹤0.01% of the portfolio and ranks #1627 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in IOVA as recently as Q4 2018.

Pathstone Family Office first reported a position in IOVA in Q3 2017 and has held it in 7 quarters since. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

Pathstone Family Office held 10,519 shares of Iovance Biotherapeutics worth $47.9K as of Q3 2023.
Iovance Biotherapeutics was a new Pathstone Family Office position in Q3 2023.
Iovance Biotherapeutics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1627 holding.
Pathstone Family Office first reported a position in Iovance Biotherapeutics in Q3 2017 and has held it in 7 quarters since.
227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.